Dabholkar M, Advani S, Tatake R, Gangal S
Leuk Res. 1986;10(2):203-9. doi: 10.1016/0145-2126(86)90043-3.
Non-adherent peripheral blood mononuclear cells (NA-PBMNC) from 67 chronic myeloid leukemia (CML) patients in the first and two subsequent remissions, and 23 normal healthy donors were tested for NK and ADCC activities in short term chromium release assays using K562 and antibody-coated chicken RBCs as respective targets. CML patients in remission exhibited significantly reduced NK cytotoxicity (16. 1-19.7%) compared to normal healthy donors (47.4%). Of the patients tested, 55% exhibited NK levels below the mean percent cytotoxicity--2SD (12.5%) of normal donors (low responders), while 45% exhibited NK cytotoxicity above the 12.5% level (normal responders). On the other hand, CML patients in remission showed ADCC activity comparable to that of normal healthy donors (53.3%) irrespective of whether they belonged to normal NK responder group (55.5-65.0% ADCC) or low NK responder group (39.4-48.3% ADCC). The low or normal NK responder status of CML patients was not found to be related to either progression on the disease, or the type of drug used to bring about remission, or to the period in remission at the time of testing. In-vitro treatment of effector lymphocytes with recombinant human IFN alpha resulted in augmented of NK activity in both low and normal NK responder patients. The IFN-augmented NK activity in low responder patients however remained below the normal levels.
对67例处于首次缓解期及随后两次缓解期的慢性髓性白血病（CML）患者的非贴壁外周血单个核细胞（NA-PBMNC）以及23名正常健康供者的细胞，在短期铬释放试验中使用K562和抗体包被的鸡红细胞分别作为靶细胞，检测其NK和ADCC活性。与正常健康供者（47.4%）相比，缓解期的CML患者NK细胞毒性显著降低（16.1 - 19.7%）。在检测的患者中，55%的患者NK水平低于正常供者细胞毒性平均百分比减去2个标准差（12.5%）（低反应者），而45%的患者NK细胞毒性高于12.5%水平（正常反应者）。另一方面，缓解期的CML患者无论属于正常NK反应者组（ADCC为55.5 - 65.0%）还是低NK反应者组（ADCC为39.4 - 48.3%），其ADCC活性与正常健康供者相当（53.3%）。未发现CML患者的低或正常NK反应者状态与疾病进展、用于诱导缓解的药物类型或检测时的缓解期时长有关。用重组人干扰素α对效应淋巴细胞进行体外处理，可使低NK反应者和正常NK反应者患者的NK活性均增强。然而，低反应者患者中经干扰素增强后的NK活性仍低于正常水平。
